SLNO SOLENO THERAPEUTICS INC

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Biopharmaceutical company developing and commercializing novel therapeutics for rare diseases, with initial focus on Prader-Willi syndrome (PWS)
• • New product: FDA approval and first commercial sales of VYKAT XR (diazoxide choline extended-release tablets) for hyperphagia in PWS patients aged 4 and older in March 2025
• • Strategic shift: Transition from clinical development to commercialization phase with a 65-person U.S. field force targeting PWS specialists and multidisciplinary care teams
• • Quantitative metric: Identified PWS patient population approx. 10,000 in U.S. with growing diagnosis rates; product priced at $6.0976 per mg with global patent protection expiring 2026-2035
• • Noteworthy fact: In February 2026, new U.S. legislation codified FDA’s interpretation allowing multiple orphan drug approvals for different subpopulations within the same rare disease, impacting market exclusivity and competition strategy

Risk Factors

• • Regulatory risk: FDA approval of VYKAT XR in March 2025 triggered contingent payments of $7.0 million due Q1 2026
• • Macroeconomic exposure: $50 million outstanding loan with Oxford at 1-month SOFR + 5.50% interest, with $100 million more contingent on mutual consent
• • Operational risk: Manufacturing and supply chain costs included in $40.6 million R&D spend, reduced by $7.5 million from prior year NDA support
• • Competitive risk: Commercial launch costs increased by $23.4 million for marketing and commercial programs supporting VYKAT XR sales
• • Financial risk: Contingent liability for milestone payments up to $21.2 million linked to VYKAT XR sales milestones of $100 million and $200 million

Management Discussion & Analysis

• • No revenue or YoY change figures disclosed
• • No profitability or operating margin data provided
• • No segment performance data included
• • No cash flow, buybacks, dividends, or capex amounts stated
• • Forward-looking statements highlight risks including maintaining profitability, capital needs, intellectual property, regulatory approvals, and market competition

What are the latest SLNO SEC filings in 2026?

SOLENO THERAPEUTICS INC (SLNO) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on May 18, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did SLNO file its most recent 10-K annual report?

SOLENO THERAPEUTICS INC (SLNO) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view SLNO 10-Q quarterly reports?

SOLENO THERAPEUTICS INC (SLNO)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every SLNO 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has SLNO filed recently?

SOLENO THERAPEUTICS INC (SLNO)'s most recent 8-K was filed on May 18, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find SLNO insider trading activity (Form 4)?

SignalX aggregates every SLNO Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does SLNO file with the SEC?

SOLENO THERAPEUTICS INC (SLNO) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new SLNO filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for SOLENO THERAPEUTICS INC (SLNO).

What is SLNO's SEC CIK number?

SOLENO THERAPEUTICS INC (SLNO)'s SEC CIK (Central Index Key) number is 1484565. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1484565 to look up all SLNO filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find SLNO return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from SOLENO THERAPEUTICS INC (SLNO) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.